At the 2026 ASCRS Annual Meeting in Washington, DC, several presentations converged on a set of questions that define the ...
Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision ...
RMAT designation enables intensified FDA engagement and potential accelerated pathways, implying preliminary clinical evidence for RTx-015 despite absent peer-reviewed efficacy details, endpoints, and ...
Opus Genetics and Viatris (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants exclusive rights ...
One night, Tomás realized something was seriously wrong. He went for a stroll, along the same paths near his village that he ...
It is part of Derrick H. Pitts’ nature that he can vividly recall the sky conditions over this village when he visited St. Lawrence University in the mid-1970s as a soon-to-be student “I had ...
Ocular Therapeutix Inc. OCUL shares are up on Monday following the announcement of additional positive data from the SOL-1 ...
Outlook Therapeutics OTLK announced on Monday that it has submitted a formal dispute resolution request (FDRR) to the U.S.
Red light therapy has long been used by humans to improve skin health, slow visible ageing and soothe muscle. Could it help ...
Luminopia has a clinically meaningful benefit for children with severe amblyopia, according to a study presented at the ...
Happy Monday, Philly. We’re in for a cloudy day, and then warmer temps later in the week. Philadelphia police have expanded their use of drones, without the transparency and oversight that’s seen in ...
IDEAYA Biosciences (IDYA) nears key phase 3 darovasertib data in uveal melanoma, with 3–4 years cash runway and FDA potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results